Pharmaceutical Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization application to the European Medicines Agency for the approval of IDegLira, the combination product of insulin degludec (Tresiba, the once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza, the once-daily human GLP-1 analogue. IDegLira has been developed for the treatment of people with type 2 diabetes. 31 May 2013